Ophiuchus Technologies is the first globally to repair the brain and spinal cord by mimicking the salamander’s regeneration capacity through its game-changing DrSC™ technology in human application.
DrSC™ Neural are organ-specific and are the first neural stem cells produced that have full competence for functional integration in the brain and spinal cord.
First indications: Spinal Cord Injury and Traumatic Brain Injury.
Clinical development: First-in-man clinical trial in Spinal Cord Injury approved; planned patient recruitment to start in summer of 2014.
The unique DrSC™ technology permits the creation of Directly reprogrammed Stem Cells (DrSC™) from a patient’s own (autologous) mature, accessible cells (e.g. blood cells) without going through a pluripotency state, which essentially eliminates the risk of tumor formation and overcomes a number of safety challenges.
Ophiuchus Technologies AG is a NOVAGENESIS company based out of Switzerland.
(“Ophiuchus”; pronounced [äˈfiSHəs], the 13th star sign representing the god / source of medicine and rebirth.)
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2013
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Ophiuchus Technologies AG founded?
Ophiuchus Technologies AG was founded in 2013.
What industry is Ophiuchus Technologies AG in?
Ophiuchus Technologies AG operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Find investors for your startup like Ophiuchus Technologies AG
Gritt sends AI-personalised outreach to each investor — from your Gmail